Preferred Label : Pamlectabart Tismanitin;
NCIt synonyms : ADC HDP-101; Anti-BCMA Antibody-drug Conjugate HDP-101; Anti-BCMA/Alpha-amanitin ADC HDP-101; Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101;
NCIt definition : An antibody-drug conjugate (ADC) consisting of pamlectabart, a humanized immunoglobulin
G1-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation
antigen (BCMA, TNFRSF17) conjugated with tismanitin, which consists of a cleavable
linker and the cytotoxic, RNA polymerase II inhibitor alpha-amanitin, with potential
antineoplastic activity. Upon administration of pamlectabart tismanitin, the pamlectabart
moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer
cells. Upon antibody/antigen binding, internalization and cleavage, the cytotoxic
alpha-amanitin is released. Alpha-amanitin binds to and inhibits RNA polymerase II,
prevents RNA synthesis, induces apoptosis, and inhibits the proliferation of BCMA-overexpressing
tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis
factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF),
is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key
role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed
on malignant plasma cells.;
UNII : CZ3K2AB2XK;
CAS number : 2925692-67-5;
Molecule name : HDP-101; HDP 101;
NCI Metathesaurus CUI : CL1662215;
Origin ID : C179409;
UMLS CUI : C5555666;
Semantic type(s)
- concept_is_in_subset
- has_target
